for oral use Initial U.S. Approval: 1998
capecitabine is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuv ant Colon Cancer –Patients with Dukes’ C colon cancer • Metastatic Colorectal Cancer –First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer –In combination with docetaxel after failure of prior anthracyclinecontaining therapy –As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen
Facts about capecitabine tablets
Approval Date: 1998
Proprietary Name: On Request
Active Ingredient(s): capecitabine tablets
Dosage Forms And Strengths: Tablets: 150 mg and 500 mgTablets: 150 mg and 500 mg
Current indications: Breast cancer, Colorectal cancer, Pancreatic adenocarcinoma, Stomach (gastric) cancer, esophageal cancer, or gastroesophageal junction cancer in adults, Stomach (gastric) cancer or gastroesophageal junction cancer in adults.
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import capecitabine tablets” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.